VTGN — Vistagen Therapeutics Share News
0.000.00%
Last trade - 00:00- $7.97m
- -$23.76m
- $1.27m
VistaGen fiscal Q3 net loss widens to $18.9 mln
Brief: VistaGen Q3 EPS USD -0.45
U.S. RESEARCH ROUNDUP- Autozone, Coursera, Lennar
NASDAQ RESUMED AT 09:00 AM
Brief: Vistagen Announces Topline Results From Palisade-3 Phase 3 Study
NASDAQ TRADE HALT HALT NEWS PENDING AT 08:25 AM
Brief: Vistagen Appoints Nick Tressler As Chief Financial Officer
Biopharmaceutical firm VistaGen's fiscal Q2 net loss widens
Brief: VistaGen Q2 EPS USD -0.54
Brief: Vistagen Appoints Paul Edick To Its Board Of Directors
Brief: Vistagen Therapeutics CFO Cynthia L. Anderson Resigns - SEC Filing
Vistagen Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Biopharmaceutical firm VistaGen Q1 net loss widens
Vistagen Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Vistagen Appoints Elissa Cote As Chief Corporate Development Officer
Vistagen Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview
Vistagen Therapeutics Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial
Vistagen Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary